EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparing TAVR and SAVR in the Treatment of Aortic Stenosis

Ricky Patil, Sanjhai Ramdeen, Matthew Kazaleh, Gorav Ailawadi

The Heart Surgery Forum · 29.06.2026 · 29 (6)

DOI: 10.31083/hsf49530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Heart Surgery Forum, online erschienen am 29.06.2026. Verfasst von Ricky Patil und 3 weiteren Autor:innen. Die Arbeit nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart, Lung, and Blood Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aortic stenosis (AS) is the most commonly treated valvulopathy worldwide, affecting more than 9.4 million patients. Surgical aortic valve replacement (SAVR) has long been the standard treatment for severe AS. As a less invasive approach that avoids open-heart surgery, transcatheter aortic valve replacement (TAVR) has rapidly gained popularity and is now a first-line treatment modality for many patients with AS. Multiple large prospective trials have demonstrated the non-inferiority of TAVR compared with SAVR with respect to survival and other key clinical endpoints. However, long-term data on valve durability and function after TAVR remain limited in select populations. This is particularly important for younger TAVR recipients, whose life expectancy may exceed the functional lifespan of the valve. Furthermore, the efficacy and safety of TAVR in certain patient subsets, such as those with bicuspid aortic valves (BAVs) or a small aortic annulus (SAA), remain uncertain. In contrast, SAVR continues to provide excellent outcomes across a broad range of valve anatomies. Additionally, surgical implantation of a mechanical valve or a pulmonary autograft via the Ross procedure remains an excellent option for appropriately selected younger surgical candidates. A surgical approach also allows for adjunct procedures, such as aortic annular enlargement, which can be particularly beneficial in patients with smaller aortic annuli. Overall, the data comparing SAVR and TAVR is extensive and continues to evolve. This manuscript aims to review the key studies and provide an overview of contemporary treatment options for AS.

Förderung

  • National Heart, Lung, and Blood Institute

Zitieren

APA

Patil, R., Ramdeen, S., Kazaleh, M., & Ailawadi, G. (2026). Comparing TAVR and SAVR in the Treatment of Aortic Stenosis. The Heart Surgery Forum, 29(6). https://doi.org/10.31083/hsf49530

Vancouver

Patil R, Ramdeen S, Kazaleh M, Ailawadi G. Comparing TAVR and SAVR in the Treatment of Aortic Stenosis. The Heart Surgery Forum. 2026;29(6). doi:10.31083/hsf49530

BibTeX
@article{Patil2026,
  author = {Patil, Ricky and Ramdeen, Sanjhai and Kazaleh, Matthew and Ailawadi, Gorav},
  title = {Comparing TAVR and SAVR in the Treatment of Aortic Stenosis},
  journal = {The Heart Surgery Forum},
  year = {2026},
  volume = {29},
  number = {6},
  doi = {10.31083/hsf49530}
}
Kostenlos starten →